We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+1.55%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.06T
AUM Growth
-$16.9B
Cap. Flow
-$16.2B
Cap. Flow %
-1.53%
Top 10 Hldgs %
26.1%
Holding
3,048
New
131
Increased
1,029
Reduced
1,524
Closed
112

Top Buys

Rank Stock Value
1
XYZ
Block Inc
XYZ
+$2.39B
2
CVNA icon
Carvana
CVNA
+$1.82B
3
MSFT icon
Microsoft
MSFT
+$1.5B
4
DIS icon
Walt Disney
DIS
+$1.25B
5
SPOT icon
Spotify
SPOT
+$1.05B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$2.65B
2
INTU icon
Intuit
INTU
+$2.08B
3
MTCH icon
Match Group
MTCH
+$1.87B
4
CRM icon
Salesforce
CRM
+$1.76B
5
META icon
Meta Platforms (Facebook)
META
+$1.61B

Sector Composition

Rank Sector Weight
1 Technology 25.08%
2 Healthcare 16.24%
3 Consumer Discretionary 15.33%
4 Communication Services 13.82%
5 Financials 12.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BRSL
2676
Brightstar Lottery PLC
BRSL
$2.15B
$220K ﹤0.01%
8,374
-123
-1% -$2.61K
KRYS icon
2677
Krystal Biotech
KRYS
$9.72B
$220K ﹤0.01%
4,219
NGS icon
2678
Natural Gas Services Group
NGS
$474M
$220K ﹤0.01%
21,188
MERC icon
2679
Mercer International
MERC
$33.8M
$219K ﹤0.01%
18,925
SYRS
2680
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$219K ﹤0.01%
+4,908
New +$240K
RYTM icon
2681
Rhythm Pharmaceuticals
RYTM
$7.99B
$218K ﹤0.01%
16,712
VSEC icon
2682
VSE Corp
VSEC
$6.48B
$218K ﹤0.01%
4,535
MRTN icon
2683
Marten Transport
MRTN
$1.24B
$217K ﹤0.01%
13,822
+109
+0.8% +$1.71K
DSGR icon
2684
Distribution Solutions Group
DSGR
$1.61B
$216K ﹤0.01%
8,638
AMPE
2685
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$215K ﹤0.01%
431
+2
+0.5% +$927
EFC
2686
Ellington Financial
EFC
$1.76B
$214K ﹤0.01%
11,718
+284
+2% +$5.21K
HCC icon
2687
Warrior Met Coal
HCC
$4.98B
$213K ﹤0.01%
+9,157
New +$185K
CASH icon
2688
Pathward Financial
CASH
$1.79B
$212K ﹤0.01%
4,049
+63
+2% +$3.13K
LBAI
2689
DELISTED
Lakeland Bancorp Inc
LBAI
$212K ﹤0.01%
12,013
NKTX icon
2690
Nkarta
NKTX
$165M
$211K ﹤0.01%
7,596
+98
+1% +$3.1K
RLMD icon
2691
Relmada Therapeutics
RLMD
$507M
$211K ﹤0.01%
+8,057
New +$216K
PRMW
2692
DELISTED
Primo Water Corporation
PRMW
$211K ﹤0.01%
13,412
+374
+3% +$6.3K
ROCC
2693
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
$211K ﹤0.01%
+7,919
New +$156K
RIGL icon
2694
Rigel Pharmaceuticals
RIGL
$762M
$210K ﹤0.01%
5,796
+111
+2% +$4.37K
FLXN
2695
DELISTED
Flexion Therapeutics, Inc.
FLXN
$210K ﹤0.01%
34,451
+15,393
+81% +$95.9K
LORL
2696
DELISTED
Loral Space and Communications, Inc.
LORL
$210K ﹤0.01%
+4,874
New +$189K
CLB icon
2697
Core Laboratories
CLB
$569M
$208K ﹤0.01%
7,500
-1,100
-13% -$33.5K
INOD icon
2698
Innodata
INOD
$2.03B
$208K ﹤0.01%
21,800
EVOP
2699
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
$208K ﹤0.01%
+8,763
New +$233K
HSTM icon
2700
HealthStream
HSTM
$849M
$207K ﹤0.01%
7,253
-9,101
-56% -$266K

Similar funds

T. Rowe Price Associates's Q3 2021 Portfolio in Review

As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
  • T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
  • T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
  • T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
  • T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
  • T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.